APA (7th ed.) Citation

Liu, X., Shaw, R. H., Stuart, A. S. V., Greenland, M., Aley, P. K., Andrews, N. J., . . . Lambe, T. (2021). Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): A single-blind, randomised, non-inferiority trial. Lancet, 398(10303), 856. https://doi.org/10.1016/S0140-6736(21)01694-9

Chicago Style (17th ed.) Citation

Liu, Xinxue, et al. "Safety and Immunogenicity of Heterologous Versus Homologous Prime-boost Schedules with an Adenoviral Vectored and MRNA COVID-19 Vaccine (Com-COV): A Single-blind, Randomised, Non-inferiority Trial." Lancet 398, no. 10303 (2021): 856. https://doi.org/10.1016/S0140-6736(21)01694-9.

MLA (9th ed.) Citation

Liu, Xinxue, et al. "Safety and Immunogenicity of Heterologous Versus Homologous Prime-boost Schedules with an Adenoviral Vectored and MRNA COVID-19 Vaccine (Com-COV): A Single-blind, Randomised, Non-inferiority Trial." Lancet, vol. 398, no. 10303, 2021, p. 856, https://doi.org/10.1016/S0140-6736(21)01694-9.